Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01781637 · ClinicalTrials.gov registry record · Phase 1
Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial
A Phase 1 study of Food Allergy and Peanut Allergy, sponsored by Boston Children's Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 4
- Study locations
NCT01781637 is a Phase 1 study of Food Allergy and Peanut Allergy that has completed, run by Boston Children's Hospital. The registered enrollment target is 36 participants, below the 962-participant average among 17 other Food Allergy trials with a reported enrollment target (96% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT01781637, a Phase 1 study of Food Allergy and Peanut Allergy, has completed, sponsored by Boston Children's Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 4
- Study locations
Study Summary
The investigators will perform a double blind, placebo controlled clinical trial with Xolair (omalizumab) at four centers to safely and rapidly desensitize patients with severe peanut allergy. The investigators will determine if pretreatment with anti-IgE mAb (Xolair/omalizumab) can greatly reduce allergic reactions and allow for faster and safer desensitization.
Conditions Studied
Interventions
- DRUG placebo
- DRUG Omalizumab
Study Locations (4)
California
- Stanford University - Stanford
Illinois
- Lurie Children's Hospital - Chicago
Massachusetts
- Division of Immunology, Children's Hospital Boston - Boston
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2013-01 |
| Est. Completion | 2022-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01781637
The ClinicalTrials.gov registry entry for NCT01781637 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 962-participant average among 17 other Food Allergy trials with a reported enrollment target (96% lower). The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Food Allergy appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT01781637 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Illinois, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01781637 about?
NCT01781637 is a clinical study titled "Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial". The investigators will perform a double blind, placebo controlled clinical trial with Xolair (omalizumab) at four centers to safely and rapidly desensitize patients with severe peanut allergy. The investigators will determine if pretreatment with anti-IgE mAb (Xolair/omalizumab) can greatly reduce a...
What is the current status of trial NCT01781637?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2013-01. Estimated completion is 2022-05-31.
What conditions does trial NCT01781637 study?
This clinical trial studies the following conditions: Food Allergy, Peanut Allergy.
What interventions are being tested in trial NCT01781637?
The interventions under investigation include: placebo (DRUG), Omalizumab (DRUG).
Who is sponsoring clinical trial NCT01781637?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01781637 being conducted?
This trial has 4 study locations across California, Illinois, Massachusetts, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Food Allergy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy
RECRUITING · Phase 1
-
PK/PD Study of IN-001 Sublingual Spray in Healthy Adults
RECRUITING · Phase 1
-
ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults
COMPLETED · Phase 1
-
Effect of Omalizumab in the Skin of Food Allergy Patients
RECRUITING · Phase 4
-
Data and Sample Collection Study to Elucidate the Mechanisms of Eosinophilic Disorders
RECRUITING
-
Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.